Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Microchip Technology Screens for More Than 1000 Molecules

By LabMedica International staff writers
Posted on 06 Aug 2009
Scientists have developed technology to perform over a thousand chemical reactions at once on a stamp-size, PC-controlled microchip.

The technology, which is based on microfluidics, utilized miniaturized devices to automatically handle and channel tiny amounts of liquids and chemicals invisible to the eye. More...
The chemical reactions were performed using in situ click chemistry, and analyzed using mass spectrometry.

A thousand cycles of complex processes, including controlled sampling and mixing of a library of reagents and sequential microchannel rinsing, all took place on the microchip device and were completed in a few hours. Developed by a University of California, Los Angeles (UCLA; Los Angeles, CA, USA) team, the technology is restricted to analyzing the reaction results offline, but the aim is to automate this aspect of the work also. It could accelerate the identification of potential drug candidates for treating diseases like cancer.

The team intends to utilize the technology for diagnostic screening reactions in which chemicals and material samples are in limited supply; e.g., protein enzymes such as kinases that play critical roles in the malignant transformation of cancer. According to the scientists, the technology will open up many areas for biologic and medicinal study.

"The precious enzyme molecules required for a single in situ click reaction in a traditional lab now can be split into hundreds of duplicates for performing hundreds of reactions in parallel, thus revolutionizing the laboratory process, reducing reagent consumption and accelerating the process for identifying potential drug candidates," said study author Prof. Hsian-Rong Tseng, scientist at UCLA's Crump Institute for Molecular Imaging, associate professor molecular and medical pharmacology at the David Geffen School of Medicine at UCLA, and a member of the California NanoSystems Institute at UCLA.

The Study appeared online in the August 2009 edition of Science Daily.

Related Links:
University of California, Los Angeles
Science Daily


Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
All-in-One Molecular System
AIO M160
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: The study compares rapid molecular CPE diagnostics, which can return results in about one hour, with culture-based screening, which typically takes about 48 hours (Image credit: Adobe Stock)

Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE

Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read more

Pathology

view channel
Image: The VENTANA PTEN (SP218) RxDx Assay is a qualitative IHC assay for assessing PTEN protein in prostate adenocarcinoma, with staining performed using the OptiView DAB IHC Detection Kit on a BenchMark ULTRA instrument (Photo courtesy of Roche)

New Companion Diagnostic Expands Precision Medicine in Prostate Cancer

Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.